Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.50, implying a 14.97% upside from current levels. In a report released yesterday, Bernstein also maintained a Hold rating ...

John G Ullman & Associates Inc. made a hefty bet on Regeneron Pharmaceuticals, upping their stake by a whopping 94%, now ...

Regeneron Pharmaceuticals is on the cusp of unveiling its Q2 2025 earnings this Friday, with expectations pinned at $8.53 per share and a revenue forecast of $3.30 billion. Analysts are eyeing a ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

Wall Street analysts forecast that Regeneron (REGN) will report quarterly earnings of $8.03 per share in its upcoming release, pointing to a year-over-year decline of 30.5%. It is anticipated that ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Sanofi, with a price target of €100.00. The company’s shares closed yesterday at $95.42. Take advantage of ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.